Coenzyme
Q10 Increases Post-CPR Survival
Newswire (February 24, 2005)—Combining coenzyme Q10 (CoQ10)
supplementation with hypothermia therapy increases survival and
might prevent neurological damage in people who have received
CPR (cardiopulmonary resuscitation) after a heart attack, according
to Circulation (2004;110:3011–6).
CPR is a technique used to restore the heartbeat
and breathing immediately after events such as a heart attack
or a major trauma. Despite its lifesaving potential, about 88%
of people who have been resuscitated with CPR die before they
are able to leave the hospital; of those who survive, more than
90% have permanent brain or nerve damage that leaves them partially
or completely disabled. The injury to nerve tissues can occur
both during the time when there is no blood flow (before CPR)
and during the time immediately following the restoration of blood
flow (after CPR), a phenomenon known as “reperfusion injury.”
Two studies have found that keeping the person in a state of mild
hypothermia (subnormal body temperature) for 24 hours after resuscitation
can reduce nerve damage from reperfusion injury and increase the
likelihood of recovery.
CoQ10, a nutrient found throughout the body, is
an antioxidant involved in producing energy in cells. It is widely
known for its beneficial effects on heart health, including protecting
the heart muscle from damage due to lack of oxygen. CoQ10 has
recently received attention for its apparent benefit in neurological
diseases such as Alzheimer’s disease, Parkinson’s
disease, Huntington’s chorea, and Lou Gehrig’s disease
(amyotrophic lateral sclerosis). It is proposed that CoQ10 might
similarly protect nerve tissues from damage in people who have
received CPR.
Forty-nine people who had received CPR after experiencing
sudden loss of heartbeat (cardiac arrest) were included in the
current study. All participants arrived for treatment within six
hours of their cardiac arrest and were treated with mild hypothermia
therapy for the 24 hours immediately following. During hypothermia
therapy, a cooling mattress was used to maintain a body temperature
of 35 to 36°C (95 to 96.8°F); after 24 hours, the body
was slowly warmed to a normal temperature of 37°C (98.6°F).
Participants were randomly assigned to receive
either CoQ10 (250 mg upon entry to the study followed by 150 mg
three times per day for 90 days) or placebo. Neurological testing
was performed on each participant upon entry to the study, as
well as 1,3, 5, and 90 days after entry. Significantly more of
the people receiving CoQ10 (68%) than receiving placebo (29%)
were still alive at the end of the study. Furthermore, more people
using CoQ10 (36%) had good neurological function at the end of
the study than those receiving placebo (20%).
The results of this study suggest that CoQ10 combined
with mild hypothermia therapy increases survival and might reduce
neurological damage in people who received CPR after a heart attack.
Future studies are needed to verify these findings, and the optimal
amount and timing for CoQ10 supplementation needs further investigation.